key: cord-0807088-ulswubyx
authors: Hariyanto, Timotius Ivan; Kurniawan, Andree
title: Authors’ response: Metabolic and Drug-Based Approach of Obstructive Sleep Apnea (OSA) patients with COVID-19
date: 2021-06-24
journal: Sleep Med
DOI: 10.1016/j.sleep.2021.06.013
sha: 73b4e632c1878c00cc6fa7b29b31f46e59b094a3
doc_id: 807088
cord_uid: ulswubyx

nan

course of COVID-19, the use of anti-inflammatory drugs, such as ivermectin, which is given during the late course of the disease before multi-organ failure happened is also strongly suggested for further controlling the CS. Ivermectin can reduce the levels of IL-1, IL-6, and TNF-α, cytokines which are commonly elevated in severe COVID-19 patients, and also suppress the translocation of lipopolysaccharide (LPS)-induced nuclear factor-kappa B (NF-κB) translocation, therefore preventing the clinical deterioration and reducing the mortality rate from COVID-19. [5] Together with SARS-CoV-2 vaccine prioritization for people with OSA, these approach we offered may help in reducing the burden from COVID-19 in those groups of people.

J o u r n a l P r e -p r o o f

An early prevention of hypoxemia in COVID-19 patients complaining obstructive sleep apnea

Obstructive sleep apnea (OSA) and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis

Metformin induces significant reduction of body weight, total cholesterol and LDL levels in the elderly -A meta-analysis

Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection

Ivermectin and outcomes from Covid-19 pneumonia: A systematic review and meta-analysis of randomized clinical trial studies